Gene Expression Signature Associated with Clinical Outcome in ALK-Positive Anaplastic Large Cell Lymphoma

Autor: Lamant, Camille Daugrois, Chloé Bessiere, Sébastien Dejean, Véronique Anton-Leberre, Thérèse Commes, Stephane Pyronnet, Pierre Brousset, Estelle Espinos, Laurence Brugiere, Fabienne Meggetto, Laurence
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Cancers; Volume 13; Issue 21; Pages: 5523
ISSN: 2072-6694
DOI: 10.3390/cancers13215523
Popis: Anaplastic large cell lymphomas associated with ALK translocation have a good outcome after CHOP treatment; however, the 2-year relapse rate remains at 30%. Microarray gene-expression profiling of 48 samples obtained at diagnosis was used to identify 47 genes that were differentially expressed between patients with early relapse/progression and no relapse. In the relapsing group, the most significant overrepresented genes were related to the regulation of the immune response and T-cell activation while those in the non-relapsing group were involved in the extracellular matrix. Fluidigm technology gave concordant results for 29 genes, of which FN1, FAM179A, and SLC40A1 had the strongest predictive power after logistic regression and two classification algorithms. In parallel with 39 samples, we used a Kallisto/Sleuth pipeline to analyze RNA sequencing data and identified 20 genes common to the 28 genes validated by Fluidigm technology—notably, the FAM179A and FN1 genes. Interestingly, FN1 also belongs to the gene signature predicting longer survival in diffuse large B-cell lymphomas treated with CHOP. Thus, our molecular signatures indicate that the FN1 gene, a matrix key regulator, might also be involved in the prognosis and the therapeutic response in anaplastic lymphomas.
Databáze: OpenAIRE